Stifel on Regenxbio Inc. (RGNX): PT $45, 'should NOT impact RGX-202 and RGX-314'
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $45.00 price target on Regenxbio Inc. (NASDAQ: RGNX)The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
